Silva L C R, Romero T R L, Guzzo L S, Duarte I D G
Departamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.
Braz J Med Biol Res. 2012 Dec;45(12):1240-3. doi: 10.1590/s0100-879x2012007500153. Epub 2012 Sep 18.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used extensively to control inflammatory pain. Several peripheral antinociceptive mechanisms have been described, such as opioid system and NO/cGMP/KATP pathway activation. There is evidence that the cannabinoid system can also contribute to the in vivo pharmacological effects of ibuprofen and indomethacin. However, there is no evidence of the involvement of the endocannabinoid system in the peripheral antinociception induced by NSAIDs. Thus, the aim of this study was to investigate the participation of the endocannabinoid system in the peripheral antinociceptive effect of NSAIDs. All experiments were performed on male Wistar rats (160-200 g; N = 4 per group). Hyperalgesia was induced by a subcutaneous intraplantar (ipl) injection of prostaglandin E2 (PGE2, 2 μg/paw) in the rat's hindpaw and measured by the paw pressure test 3 h after injection. The weight in grams required to elicit a nociceptive response, paw flexion, was determined as the nociceptive threshold. The hyperalgesia was calculated as the difference between the measurements made before and after PGE2, which induced hyperalgesia (mean = 83.3 ± 4.505 g). AM-251 (80 μg/paw) and AM-630 (100 μg/paw) were used as CB1 and CB2 cannabinoid receptor antagonists, respectively. Ipl injection of 40 μg dipyrone (mean = 5.825 ± 2.842 g), 20 μg diclofenac (mean = 4.825 ± 3.850 g) and 40 μg indomethacin (mean = 6.650 ± 3.611 g) elicited a local peripheral antinociceptive effect. This effect was not antagonized by ipl CB1 cannabinoid antagonist to dipyrone (mean = 5.00 ± 0.9815 g), diclofenac (mean = 2.50 ± 0.8337 g) and indomethacin (mean = 6.650 ± 4.069 g) or CB2 cannabinoid antagonist to dipyrone (mean = 1.050 ± 6.436 g), diclofenac (mean = 6.675 ± 1.368 g) and indomethacin (mean = 2.85 ± 5.01 g). Thus, cannabinoid receptors do not seem to be involved in the peripheral antinociceptive mechanism of the NSAIDs dipyrone, diclofenac and indomethacin.
非甾体抗炎药(NSAIDs)已被广泛用于控制炎性疼痛。已描述了几种外周抗伤害感受机制,如阿片系统和NO/cGMP/KATP途径的激活。有证据表明,大麻素系统也可促成布洛芬和吲哚美辛的体内药理作用。然而,尚无证据表明内源性大麻素系统参与NSAIDs诱导的外周抗伤害感受。因此,本研究的目的是调查内源性大麻素系统在NSAIDs外周抗伤害感受作用中的参与情况。所有实验均在雄性Wistar大鼠(160 - 200 g;每组N = 4)上进行。通过在大鼠后爪足底皮下注射前列腺素E2(PGE2,2 μg/爪)诱导痛觉过敏,并在注射后3小时通过爪压力试验进行测量。引发伤害性反应(爪屈曲)所需的以克为单位的重量被确定为伤害性阈值。痛觉过敏计算为PGE2诱导痛觉过敏前后测量值的差值(平均值 = 83.3 ± 4.505 g)。AM - 251(80 μg/爪)和AM - 630(100 μg/爪)分别用作CB1和CB2大麻素受体拮抗剂。足底注射40 μg安乃近(平均值 = 5.825 ± 2.842 g)、20 μg双氯芬酸(平均值 = 4.825 ± 3.850 g)和40 μg吲哚美辛(平均值 = 6.650 ± 3.611 g)可引发局部外周抗伤害感受作用。这种作用未被安乃近(平均值 = 5.00 ± 0.9815 g)、双氯芬酸(平均值 = 2.50 ± 0.8337 g)和吲哚美辛(平均值 = 6.650 ± 4.069 g)的足底CB1大麻素拮抗剂或安乃近(平均值 = 1.050 ± 6.436 g)、双氯芬酸(平均值 = 6.675 ± 1.368 g)和吲哚美辛(平均值 = 2.85 ± 5.01 g)的足底CB